Bio-IT World March 23, 2021

TRENDS FROM THE TRENCHES—It’s been a little over a year since Eric Dishman stepped down as CEO of the National Institutes of Health’s All of Us program and took on the role of Chief Innovation Officer. Before his time building the All of Us research program, Dishman served as an Intel fellow and vice president of the Health and Life Sciences Group at Intel Corporation.

But when he sat down to catch up with Stan Gloss, founding partner at the BioTeam, he credited much of his innovative thinking to even earlier experiences: his own 23-year journey as a cancer patient—finally cured thanks to precision medicine; his internship at Paul Allen’s think tank, Interval; and his early training in acting...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Interview / Q&A, Patient / Consumer, Pharma / Biotech, Precision Medicine, Provider, Trends
23andMe: What If …
23andMe CEO Anne Wojcicki considers taking company private
Age of Opportunity: Artificial Intelligence and the Precision Medicine Future
Opinion: Readers respond to OTC antidepressants, personalized medicine, restoring trust in public health, and more
Precision medicine approach combining AI, DNA and drug testing shows gains against relapsed childhood cancers

Share This Article